Expanding Oligonucleotide Therapeutics into Pain: Platform-Enabled Targeting of NaV1.7
9:00 am - Friday 21st August 2026
- Leveraging antisense oligonucleotides (ASOs) to modulate NaV1.7 expression as a novel non-opioid therapeutic strategy for chronic pain
- Positioning pain as an emerging and underexplored indication for oligonucleotide therapeutics beyond rare genetic and neurodegenerative diseases
- Applying AI and machine learning–enabled approaches to optimize ASO sequence and chemistry selection, improving target engagement and therapeutic index in preclinical development
